# Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

> **NCT06857240** · PHASE2 · RECRUITING · sponsor: **The Cleveland Clinic** · enrollment: 15 (estimated)

## Conditions studied

- Dermatomyositis

## Interventions

- **DRUG:** Ruxolitinib Topical Cream

## Key facts

- **NCT ID:** NCT06857240
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06857240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06857240, "Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06857240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*